Keywords
How to Cite
Abstract
We examined 100 patients with non-small cell lung cancer (NSCLC). In addition to surgery there was performed neoadjuvant chemotherapy (2-3 cycles) EP (cisplatin at a dose of 80 mg/m2 on first day + etoposide at a dose of 120 mg/ m2 on days 1,3,5). There were studied the levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) as prognostic factors in the use of neoadjuvant chemotherapy in patients with NSCLC. The control group consisted of 30 healthy volunteers. The baseline level of bFGF was necessary for the prediction of combined treatment in patients with NSCLC stage III. The threshold value bFGF>10,2 ng/ml allowed predicting a good effect from chemotherapy with a sensitivity of 71,4% and specificity of 80,6%, while the sensitivity of VEGF in terms of forecasting bicycles reached 42,9 %. The resulting algorithm for predicting of the effect of neoadjuvant chemotherapy of patients with NSCLC provided perspectives to improve the outcomes of such patients.References
Бисенков Л. Н., Гришаков С. В., Шалаев С. А. Хирургия рака легкого в далеко зашедших стадиях заболевания. СПб. : Гиппократ, 1998. - 379 с.
Миллер С. В., Тузиков С. А., Гольдберг В. Е. и др. Неоадъювантная химиотерапия в комбинированном лечении немелкоклеточного рака легкого // Росс. онкол. журнал. - 2009. - № 2. - С. 31-34.
Поддубная И. В. Онкология. Справочник практического врача. М: Медпресс-Информ, 2009. - 768 с.
Полежаев А. А., Ступина С. В., Булатова О. Н. Опыт комбинированного лечения немелкоклеточного рака легкого с применением неоадъювантной полихимиотерапии // Росс. онкол. журнал. - 2008. - № 4. - С. 31-35.
Трахтенберг А. Х., Колбанов К. И. Рак легкого / Под ред. В. И. Чиссова. - М. :ГЭОТАР-Медиа. - 2014. -160 с.
Рыбас А. Н., Шутов В. А., Рыбас А. В. и др. Изучение уровня сосудистого эндотелиального фактора роста и основного фактора роста фибробластов в комбинированном лечении больных немелкоклеточным раком легкого III стадии с использованием неоадьювантной химиотерапии и хирургического лечения // Вопр. онкол. - 2014. - Т. 60. - № 6. - С. 741-744.
Berghmans T., Paesmans M., Meert A. P. et al. Survival improvement in resectable non-small cell lung cancer with (neo) adjuvant chemotherapy: results of a meta-analysis of the literature // Lung Cancer. - 2005. - № 49. - Р 3-23.
Burdett S., Stewart L. A., Rydzewska L. A systematic review and metaanalysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer // J. Thorac. Oncol. - 2006. - № 1. - Р 611-621.
Butts C., Murray N., Maksymiuk A. et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV nonsmall-cell lung cancer // J. Clin. Oncol. - 2005. - Vol. 23. - P 6674-6681.
Cappuzzo F., Hirsch F. R., Rossi E. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer // J. Natl. Cancer. Inst. - 2005. - Vol. 97. - P. 643-655.
Eriksson P., Brattstrom D., Hesselius P. et al. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment // Neoplasma. - 2006. - № 53 (4). - P. 285-290.
Iwasaki A., Kuwahara M., Yoshinaga Y. et al. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognosis indicators in NSCLC // Eur. J. Cardiothorac. Susg. - 2004. - № 25 (3). - P. 442-448.
Hansen H. H., Bunn P. A. Lung cancer therapy // Taylor&Francis. - 2005. - P. 65-105.
Linderholm B., Grankvist K., Wilking N. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment // J. Clin. Oncol. - 2000. -Vol. 18. - P. 1423-1431.
Olaussen K. A., Dunant A., Fouret P et al. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy // The New Еngland journal of Medicine. - 2006. - Vol. 355. - Р 983-991.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...